DFDA

Pimavanserin

Treatment for Lewy Body Dementia

Typical Dosage: 34 mg once daily

Effectiveness
65%
Safety Score
55%
Clinical Trials
2
Participants
2.2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
34 mg once daily
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
18(Treat 18 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$45,000
Monitoring:$750
Side Effect Mgmt:$300
Total Annual:$46,050
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$230,250/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$102,333
Pimavanserin Outcomes

for Lewy Body Dementia

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+45%
Common Side Effects
Peripheral edema
+8%
Nausea
+7%
Confusion
+4%
QT prolongation
+0.5%

Sources:

lbda.org
nih.gov
lbda.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
1 active trial recruiting for Pimavanserin in Lewy Body Dementia

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637RECRUITINGPHASE4
View Study
94 participants
INTERVENTIONAL
San Antonio, United States +1 more
Started: Apr 22, 2022
Completed Clinical Trials
1 completed trial for Pimavanserin in Lewy Body Dementia

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556COMPLETEDPHASE3
View Study
392 participants
INTERVENTIONAL
Costa Mesa, United States +82 more
Started: Sep 27, 2017